Molecular Classification of Breast Carcinomas by Immunohistochemical Analysis: Are We Ready?
暂无分享,去创建一个
[1] Ping Tang,et al. Molecular classifications of breast carcinoma with similar terminology and different definitions: are they the same? , 2008, Human pathology.
[2] C. Perou,et al. Molecular Subtypes in Breast Cancer Evaluation and Management: Divide and Conquer , 2008, Cancer investigation.
[3] L. Crinò,et al. ERCC1 expression in triple negative breast carcinoma: the paradox revisited , 2008, Breast Cancer Research and Treatment.
[4] Robin L. Jones,et al. Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients , 2008, Breast Cancer Research and Treatment.
[5] C. Perou,et al. Epidemiology of basal-like breast cancer , 2008, Breast Cancer Research and Treatment.
[6] F. Vicini,et al. Molecular classification system identifies invasive breast carcinoma patients who are most likely and those who are least likely to achieve a complete pathologic response after neoadjuvant chemotherapy , 2007, Cancer.
[7] Harry Bartelink,et al. Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas , 2007, Breast Cancer Research.
[8] Charles M Perou,et al. FOXA1 Expression in Breast Cancer—Correlation with Luminal Subtype A and Survival , 2007, Clinical Cancer Research.
[9] S. Narod,et al. Triple-Negative Breast Cancer: Clinical Features and Patterns of Recurrence , 2007, Clinical Cancer Research.
[10] Ofra Barnett-Griness,et al. Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations. , 2007, The New England journal of medicine.
[11] R. Cress,et al. Descriptive analysis of estrogen receptor (ER)‐negative, progesterone receptor (PR)‐negative, and HER2‐negative invasive breast cancer, the so‐called triple‐negative phenotype , 2007, Cancer.
[12] C. Perou,et al. The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer Subtypes , 2007, Clinical Cancer Research.
[13] P. Bourne,et al. Expression of cytokeratin markers, ER-alpha, PR, HER-2/neu, and EGFR in pure ductal carcinoma in situ (DCIS) and DCIS with co-existing invasive ductal carcinoma (IDC) of the breast. , 2007, Annals of clinical and laboratory science.
[14] Wolfgang Heller,et al. Triple-negative breast cancer: therapeutic options. , 2007, The Lancet. Oncology.
[15] M. García-Closas,et al. Differences in Risk Factors for Breast Cancer Molecular Subtypes in a Population-Based Study , 2007, Cancer Epidemiology Biomarkers & Prevention.
[16] K. Siziopikou,et al. The basal subtype of breast carcinomas may represent the group of breast tumors that could benefit from EGFR-targeted therapies. , 2007, Breast.
[17] C. Perou,et al. Identification of a basal-like subtype of breast ductal carcinoma in situ. , 2007, Human pathology.
[18] J. Benítez,et al. Vimentin and laminin expression is associated with basal-like phenotype in both sporadic and BRCA1-associated breast carcinomas , 2006, Journal of Clinical Pathology.
[19] Ian O Ellis,et al. Prognostic markers in triple‐negative breast cancer , 2007, Cancer.
[20] D. Easton,et al. Basal-like grade III invasive ductal carcinoma of the breast: patterns of metastasis and long-term survival , 2007, Breast Cancer Research.
[21] P. Bourne,et al. Relationship between nuclear grade of ductal carcinoma in situ and cell origin markers. , 2006, Annals of clinical and laboratory science.
[22] D. Dabbs,et al. Basal phenotype of ductal carcinoma in situ: recognition and immunohistologic profile , 2006, Modern Pathology.
[23] A. Nobel,et al. Gene expression profiles do not consistently predict the clinical treatment response in locally advanced breast cancer , 2006, Molecular Cancer Therapeutics.
[24] Raymond R Tubbs,et al. Breast Cancers With Brain Metastases are More Likely to be Estrogen Receptor Negative, Express the Basal Cytokeratin CK5/6, and Overexpress HER2 or EGFR , 2006, The American journal of surgical pathology.
[25] A. Nobel,et al. Concordance among Gene-Expression – Based Predictors for Breast Cancer , 2011 .
[26] J. Bergh,et al. Basoluminal Carcinoma: A New Biologically and Prognostically Distinct Entity Between Basal and Luminal Breast Cancer , 2006, Clinical Cancer Research.
[27] A. Ashworth,et al. Basal-like breast carcinomas: clinical outcome and response to chemotherapy , 2006, Journal of Clinical Pathology.
[28] D. Easton,et al. Specific morphological features predictive for the basal phenotype in grade 3 invasive ductal carcinoma of breast , 2006, Histopathology.
[29] C. Perou,et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. , 2006, JAMA.
[30] S. Schnitt,et al. Ductal carcinoma in situ with basal-like phenotype: a possible precursor to invasive basal-like breast cancer , 2006, Modern Pathology.
[31] F. Bertucci,et al. Gene expression profiling of breast cell lines identifies potential new basal markers , 2006, Oncogene.
[32] S. Zucoloto,et al. Vascular endothelial growth factor expression in the basal subtype of breast carcinoma. , 2006, American journal of clinical pathology.
[33] P. Bourne,et al. Expression patterns of ER-alpha, PR, HER-2/neu, and EGFR in different cell origin subtypes of high grade and non-high grade ductal carcinoma in situ. , 2006, Annals of clinical and laboratory science.
[34] J. Benítez,et al. Prognostic Significance of Basal-Like Phenotype and Fascin Expression in Node-Negative Invasive Breast Carcinomas , 2006, Clinical Cancer Research.
[35] G. Hortobagyi,et al. Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[36] J. Robertson,et al. Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation , 2006, The Journal of pathology.
[37] Yan Peng,et al. Molecular alterations in columnar cell lesions of the breast , 2006, Modern Pathology.
[38] J. Reis-Filho,et al. The impact of expression profiling on prognostic and predictive testing in breast cancer , 2006, Journal of Clinical Pathology.
[39] W. Willett,et al. Diet quality is associated with the risk of estrogen receptor-negative breast cancer in postmenopausal women. , 2006, The Journal of nutrition.
[40] Alan Ashworth,et al. Distribution and significance of nerve growth factor receptor (NGFR/p75NTR) in normal, benign and malignant breast tissue , 2006, Modern Pathology.
[41] C. Perou,et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma , 2006, Modern Pathology.
[42] P. Dam,et al. Identification of cell-of-origin breast tumor subtypes in inflammatory breast cancer by gene expression profiling , 2006, Breast Cancer Research and Treatment.
[43] Manuela Gariboldi,et al. Limits of predictive models using microarray data for breast cancer clinical treatment outcome. , 2005, Journal of the National Cancer Institute.
[44] L. Ford,et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. , 2005, Journal of the National Cancer Institute.
[45] Zhao Chen,et al. Ethnicity and breast cancer: factors influencing differences in incidence and outcome. , 2005, Journal of the National Cancer Institute.
[46] Graham A Colditz,et al. Alcohol and postmenopausal breast cancer risk defined by estrogen and progesterone receptor status: a prospective cohort study. , 2005, Journal of the National Cancer Institute.
[47] D. Birnbaum,et al. Typical medullary breast carcinomas have a basal/myoepithelial phenotype , 2005, The Journal of pathology.
[48] C. Perou,et al. Molecular portraits and 70-gene prognosis signature are preserved throughout the metastatic process of breast cancer. , 2005, Cancer research.
[49] Å. Borg,et al. Cytokeratin 5/14-positive breast cancer: true basal phenotype confined to BRCA1 tumors , 2005, Modern Pathology.
[50] G. Ball,et al. High‐throughput protein expression analysis using tissue microarray technology of a large well‐characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses , 2005, International journal of cancer.
[51] Roman Rouzier,et al. Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy , 2005, Clinical Cancer Research.
[52] W. Willett,et al. Folate Intake and Risk of Breast Cancer Characterized by Hormone Receptor Status , 2005, Cancer Epidemiology Biomarkers & Prevention.
[53] Andy J. Minn,et al. Genes that mediate breast cancer metastasis to lung , 2005, Nature.
[54] Julian Peto,et al. Prediction of BRCA1 Status in Patients with Breast Cancer Using Estrogen Receptor and Basal Phenotype , 2005, Clinical Cancer Research.
[55] F. Schmitt,et al. p63, cytokeratin 5, and P-cadherin: three molecular markers to distinguish basal phenotype in breast carcinomas , 2005, Virchows Archiv.
[56] D. Stram,et al. Nonsteroidal anti-inflammatory drug use and breast cancer risk by stage and hormone receptor status. , 2005, Journal of the National Cancer Institute.
[57] Y Wang,et al. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials , 2005, The Lancet.
[58] S. Lakhani,et al. Molecular evolution of breast cancer , 2005, The Journal of pathology.
[59] C. Hudis,et al. A phase II trial of imatinib mesylate monotherapy in patients with metastatic breast cancer , 2005, Breast Cancer Research and Treatment.
[60] G. Colditz,et al. Association of hormone replacement therapy to estrogen and progesterone receptor status in invasive breast carcinoma , 2004, Cancer.
[61] Jorge S. Reis-Filho,et al. Molecular Cytogenetic Identification of Subgroups of Grade III Invasive Ductal Breast Carcinomas with Different Clinical Outcomes , 2004, Clinical Cancer Research.
[62] A. Gown,et al. Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma , 2004, Clinical Cancer Research.
[63] Puay Hoon Tan,et al. Conservation of Breast Cancer Molecular Subtypes and Transcriptional Patterns of Tumor Progression Across Distinct Ethnic Populations , 2004, Clinical Cancer Research.
[64] C. Perou,et al. Cell-Type-Specific Responses to Chemotherapeutics in Breast Cancer , 2004, Cancer Research.
[65] I. Ellis,et al. Expression of luminal and basal cytokeratins in human breast carcinoma , 2004, The Journal of pathology.
[66] Graham A Colditz,et al. Risk factors for breast cancer according to estrogen and progesterone receptor status. , 2004, Journal of the National Cancer Institute.
[67] G. Sauter,et al. KIT (CD117)-positive breast cancers are infrequent and lack KIT gene mutations. , 2004, Clinical cancer research : an official journal of the American Association for Cancer Research.
[68] L. Bégin,et al. Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. , 2004, Journal of the National Cancer Institute.
[69] M. King,et al. Breast and Ovarian Cancer Risks Due to Inherited Mutations in BRCA1 and BRCA2 , 2003, Science.
[70] A. Griffin,et al. Kin Discrimination and the Benefit of Helping in Cooperatively Breeding Vertebrates , 2003, Science.
[71] R. Tibshirani,et al. Repeated observation of breast tumor subtypes in independent gene expression data sets , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[72] M. Radmacher,et al. Pitfalls in the use of DNA microarray data for diagnostic and prognostic classification. , 2003, Journal of the National Cancer Institute.
[73] Yudong D. He,et al. A Gene-Expression Signature as a Predictor of Survival in Breast Cancer , 2002 .
[74] Horst Buerger,et al. Usual ductal hyperplasia of the breast is a committed stem (progenitor) cell lesion distinct from atypical ductal hyperplasia and ductal carcinoma in situ , 2002, The Journal of pathology.
[75] R. Tibshirani,et al. Copyright © American Society for Investigative Pathology Short Communication Expression of Cytokeratins 17 and 5 Identifies a Group of Breast Carcinomas with Poor Clinical Outcome , 2022 .
[76] Martin Eisenacher,et al. Cytogenetic Alterations and Cytokeratin Expression Patterns in Breast Cancer: Integrating a New Model of Breast Differentiation into Cytogenetic Pathways of Breast Carcinogenesis , 2002, Laboratory Investigation.
[77] G. Cevenini,et al. p53 mutation in breast cancer. Correlation with cell kinetics and cell of origin. , 2002, Journal of clinical pathology.
[78] Hermann Herbst,et al. Common Adult Stem Cells in the Human Breast Give Rise to Glandular and Myoepithelial Cell Lineages: A New Cell Biological Concept , 2002, Laboratory Investigation.
[79] Yudong D. He,et al. Gene expression profiling predicts clinical outcome of breast cancer , 2002, Nature.
[80] Van,et al. A gene-expression signature as a predictor of survival in breast cancer. , 2002, The New England journal of medicine.
[81] J. Bergh,et al. Who should not receive adjuvant chemotherapy? International databases. , 2001, Journal of the National Cancer Institute. Monographs.
[82] R. Tibshirani,et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[83] Robert J. Mayer,et al. National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1-3, 2000. , 2001, Journal of the National Cancer Institute.
[84] E. Dougherty,et al. Gene-expression profiles in hereditary breast cancer. , 2001, The New England journal of medicine.
[85] P. Ravdin,et al. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[86] J. Sudbø,et al. Gene-expression profiles in hereditary breast cancer. , 2001, The New England journal of medicine.
[87] Christian A. Rees,et al. Molecular portraits of human breast tumours , 2000, Nature.
[88] A. Goldhirsch,et al. Response to primary chemotherapy in breast cancer patients with tumors not expressing estrogen and progesterone receptors. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.
[89] P. Chappuis,et al. Clinico-pathological characteristics of BRCA1- and BRCA2-related breast cancer. , 2000, Seminars in surgical oncology.
[90] S. Gapstur,et al. Hormone receptor status of breast tumors in black, Hispanic, and non‐Hispanic white women: An analysis of 13,239 cases , 1996, Cancer.
[91] R. Blamey,et al. A prognostic index in primary breast cancer. , 1982, British Journal of Cancer.